181 related articles for article (PubMed ID: 30973040)
1. TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Torrealba N; Vera R; Fraile B; Martínez-Onsurbe P; Paniagua R; Royuela M
Aging Male; 2020 Dec; 23(5):801-811. PubMed ID: 30973040
[TBL] [Abstract][Full Text] [Related]
2. TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.
Vo BT; Morton D; Komaragiri S; Millena AC; Leath C; Khan SA
Endocrinology; 2013 May; 154(5):1768-79. PubMed ID: 23515290
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. Expression of several cytokines in prostate cancer: Correlation with clinical variables of patients. Relationship with biochemical progression of the malignance.
Torrealba N; Rodríguez-Berriguete G; Fraile B; Olmedilla G; Martínez-Onsurbe P; Guil-Cid M; Paniagua R; Royuela M
Cytokine; 2017 Jan; 89():105-115. PubMed ID: 27527810
[TBL] [Abstract][Full Text] [Related]
5. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.
Torrealba N; Rodriguez-Berriguete G; Fraile B; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Royuela M
Aging Male; 2018 Sep; 21(3):211-222. PubMed ID: 29316844
[TBL] [Abstract][Full Text] [Related]
6. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.
Koumakpayi IH; Le Page C; Mes-Masson AM; Saad F
Br J Cancer; 2010 Mar; 102(7):1163-73. PubMed ID: 20216540
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
Song K; Cornelius SC; Reiss M; Danielpour D
J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
[TBL] [Abstract][Full Text] [Related]
8. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
[TBL] [Abstract][Full Text] [Related]
9. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
10. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.
Dan HC; Cooper MJ; Cogswell PC; Duncan JA; Ting JP; Baldwin AS
Genes Dev; 2008 Jun; 22(11):1490-500. PubMed ID: 18519641
[TBL] [Abstract][Full Text] [Related]
11. NF-κB participates in chemokine receptor 7-mediated cell survival in metastatic squamous cell carcinoma of the head and neck.
Liu FY; Zhao ZJ; Li P; Ding X; Guo N; Yang LL; Zong ZH; Sun CF
Oncol Rep; 2011 Feb; 25(2):383-91. PubMed ID: 21165563
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways.
Zhu Y; Culmsee C; Klumpp S; Krieglstein J
Neuroscience; 2004; 123(4):897-906. PubMed ID: 14751283
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.
van der Poel HG
J Urol; 2004 Oct; 172(4 Pt 1):1333-7. PubMed ID: 15371835
[TBL] [Abstract][Full Text] [Related]
14. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K
Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
17. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
[TBL] [Abstract][Full Text] [Related]
18. Tormentic acid inhibits hepatic stellate cells activation via blocking PI3K/Akt/mTOR and NF-κB signalling pathways.
Lin X; Li Y; Zhang X; Wei Y; Wen S; Lu Z; Huang Q; Wei J
Cell Biochem Funct; 2021 Jan; 39(1):77-87. PubMed ID: 32564421
[TBL] [Abstract][Full Text] [Related]
19. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
Wang Q; Zhang X; Song X; Zhang L
Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
